TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06048458

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance with stress perfusion
Description: Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance with stress perfusion
Description: Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: CT coronary angiography
Description: CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease

Intervention type: DIAGNOSTIC_TEST
Intervention: CT coronary angiography
Description: CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal OCT angiography
Description: Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal OCT angiography
Description: Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sublingual microscopy (GlycoCheck)
Description: To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sublingual microscopy (GlycoCheck)
Description: To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)
Description: Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)
Description: Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
Study: NCT06401798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Methylcellulose gel was applied topically to the pocket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CWP gel
Description: Methylcellulose gel combined with CWP was applied topically to the pocket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NCWP gel
Description: Methylcellulose gel combined with NCWP was applied topically to the pocket
Study: NCT05399173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrared (gallium aluminum arsenide laser)
Description: Patient Position will be in supine \& prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment(desmopressin acetate)
Description: participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) \& advice
Study: NCT06454656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOBILE
Description: Intensive motor learning based intervention to target specific walking goals as identified using the Gait Outcome Assessment List.~Full Protocol outlining strategies available on request.~Three key principles underpin the intervention:~Principle 1: The type of task~Principle 2: The type of practice~Principle 3: The type of Feedback
Study: NCT06129149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Care-adapted and Checklist-guided ACP intervention
Description: The intervention will consist of a single one- to two-hour visit wherein the PI (Kimpel) will facilitate a flexible conversational approach with the resident (and, optionally, a healthcare decision-maker) in a quiet, private location in the resiliency hub. Using a conversation checklist adapted from a narrative synthesis of advance care planning (ACP) guides (Fahner et al., 2019), the PI will explore ACP with participants and use each visit to continually adapt the checklist and approach with trauma-informed care (TIC) principles: safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment, and choice, and cultural, historical, and gender issues. Adverse Childhood Experiences and previous death-related experiences assessed during baseline data collection will be used to tailor the discussion to carefully explore relevant history to assess resident ACP values, preferences, and goals.
Study: NCT05626712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CELZ-201 Administration
Description: Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Enhanced standard of care for Type 1 Diabetes treatment only.
Study: NCT06283212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX101
Description: ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX101
Description: ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX101
Description: ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A)
Study: NCT05612971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iAmHealthy Parents First
Description: iAmHealthy Parents first is a 3-month adult obesity treatment program targeting the unique needs of adults with school-age children. Following the iAmHealthy Parents First program, these dyads will take part in a 6-month family-based healthy lifestyles program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iAmHealthy
Description: The iAmHealthy group will receive newsletters for three months. Following this period, these dyads will take part in a 6-month family-based healthy lifestyles program.
Study: NCT04392037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide plus low-dose cyclophosphamide and dexamethasone
Description: Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
Study: NCT05132816

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high-resolution manometry
Description: High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed.
Study: NCT05439941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Study: NCT06478459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK
Description: Endoscopic ultrasound-guided intratumoral CAR-NK injection once at day 0, combined with intravenous CAR-NK infusion twice at day 4 and 5
Study: NCT06061757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging guidance with TEE and ICE for Left atrial appendage closure
Description: The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging guidance with TEE and ICE for Left atrial appendage closure
Description: The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
Study: NCT06152003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)
Description: We anticipate the intervention will contain the following: CBT for depression and trauma, Life-Steps for ART adherence, nutritional counseling, supplementary food parcels, case management, linkage to care. Specific intervention components will be informed by prior aims.
Study: NCT06361836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT777101
Description: Experimental treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT777101
Description: Experimental treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT777101
Description: Experimental treatment
Study: NCT04474353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium contrast medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Chemotherapy agent

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Description: Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2
Study: NCT05514288

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobariatric procedure
Description: Endoscopic sleeve gastroplasty or transoral outlet reduction
Study: NCT06315374

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use soft mist inhaler
Description: Only use soft mist inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use soft mist inhaler with a 3D assistive device
Description: Use soft mist inhaler with a 3D-printed assist device
Study: NCT06640101

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham IMT
Description: with 10% maximum inspiratory pressure (MIP) as the training intensity, IMT will be conducted while sitting on the chair.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: target IMT (sitting on a chair)
Description: IMT intensity identified as optimal based on the results of our ongoing study, IMT will be conducted while sitting on a chair

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: target IMT (sitting on an unstable surface)
Description: IMT intensity identified as optimal based on the results of our ongoing study, IMT will be conducted while sitting on an unstable surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The conventional treatment includes limb muscle strengthening exercises, Bobath approach, bridging exercise, balance training in standing, general gait training and activities of daily living training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The conventional treatment includes limb muscle strengthening exercises, Bobath approach, bridging exercise, balance training in standing, general gait training and activities of daily living training
Study: NCT05393128

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group (Supine Position)
Description: In this group the patients will be given supine position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be given supine position.~3. The arms and the hands will be elevated and supported, the legs will be elevated and supported.~4. The patient will be covered.~5. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Group (Right Lateral position)
Description: In this group the patients will be given right lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Group (Left Lateral position)
Description: In this group the patients will be given left lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position.
Study: NCT06320665

Intervention type: OTHER
Intervention: Radiographic measurement
Description: Measurements taken on 3D radiographs, to assess third molar inclusion and skeletal typology (vertical and sagittal)

Intervention type: OTHER
Intervention: Radiographic measurement
Description: Measurements taken on 3D radiographs, to assess third molar inclusion and skeletal typology (vertical and sagittal)

Intervention type: OTHER
Intervention: Radiographic measurement
Description: Measurements taken on 3D radiographs, to assess third molar inclusion and skeletal typology (vertical and sagittal)
Study: NCT05197595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment-based compassion therapy
Description: Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation program
Description: Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
Study: NCT06373614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: Interventions are to be performed in the evening before bedtime for 4 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bed bath
Description: Interventions are to be performed in the evening before bedtime for 4 consecutive days.
Study: NCT04969640

Intervention type: OTHER
Intervention: Optical coherence tomography
Description: Anterior segment optical coherence tomography examination of corneas with infective keratitis
Study: NCT05607615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl Beta Cyclodextrin
Description: Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5N saline as an intravenous (IV) infusion once every 28 days
Study: NCT04840004

Intervention type: DRUG
Group type: OTHER
Intervention: PVT-1
Description: Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
Study: NCT04825002

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary multimarker sensor
Description: We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.
Study: NCT06640101

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: The conventional treatment includes limb muscle strengthening exercises, Bobath approach, bridging exercise, balance training in standing, general gait training and activities of daily living training
Study: NCT06642727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: Laughter yoga reduces stress levels through sessions lasting approximately 40 minutes without any invasive or pharmacological interventions. It regulates breathing, relaxes muscles, stimulates circulation, increases pain thresholds, strengthens immunity, lightens the mind, enhances social relationships, promotes mental balance, and boosts self-esteem, hope, energy, and quality of life. The content of a session includes deep breathing exercises, warm-up exercises, childlike games, and laughter exercises.
Study: NCT06641635

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moderated hypofractionated online adaptive radiotherapy
Description: Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy~Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy~Contral group: 45Gy/25F EBRT + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors
Study: NCT06208423

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GPT-4
Description: OpenAI's GPT-4 large language model with chat interface.
Study: NCT05583877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes BOOST
Description: Participants will receive supportive care using technology for DSMT in addition to usual care.
Study: NCT06377475

Intervention type: PROCEDURE
Intervention: Jaw relation
Description: The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.

Intervention type: PROCEDURE
Intervention: Jaw relation
Description: The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.